Press Releases

Date Title and Summary Additional Formats
Toggle Summary Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer
BURLINGTON, Mass. --(BUSINESS WIRE)--Jan. 24, 2019-- ArQule , Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking
View HTML
Toggle Summary Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA)
21% objective response rate with six confirmed partial responses from 29 evaluable patients 83% disease control rate Safety profile and tolerability of continuous dosing schedule confirmed BURLINGTON, Mass. --(BUSINESS WIRE)--Jan. 9, 2019-- ArQule , Inc.’s (Nasdaq: ARQL) partner, Basilea
View HTML
Toggle Summary ArQule Added to the NASDAQ Biotechnology Index
BURLINGTON, Mass. --(BUSINESS WIRE)--Dec. 19, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 24, 2018 .
View HTML
Toggle Summary ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting
-ARQ 531 demonstrates anti-tumor activity and favorable safety profile -Dose escalation to continue - Call with management scheduled for 12/3 at 9:00 ET to discuss the results BURLINGTON, Mass. --(BUSINESS WIRE)--Dec. 3, 2018-- ArQule, Inc. (Nasdaq: ARQL) yesterday presented preliminary results
View HTML
Toggle Summary ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies
BURLINGTON, Mass. --(BUSINESS WIRE)--Nov. 29, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company’s Phase 1 dose escalation study in patients with relapsed or refractory hematologic
View HTML
Toggle Summary ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting
Presentation highlights clinical data in patients with relapsed or refractory hematologic malignancies BURLINGTON, Mass. --(BUSINESS WIRE)--Nov. 19, 2018-- ArQule, Inc. (Nasdaq:ARQL) today announced that it will present clinical data on the company’s BTK inhibitor, ARQ 531, in a poster presentation
View HTML
Toggle Summary ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium
Three poster presentations demonstrate ARQ 751’s potential as both a monotherapy and in combination with other anti-cancer agents BURLINGTON, Mass. --(BUSINESS WIRE)--Nov. 16, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced the presentation of clinical and preclinical data on ARQ 751 in three
View HTML
Toggle Summary ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Nov. 14, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Marc Schegerin, Senior Vice President, Head of Strategy, Finance, and Communication will present at the 30th Annual Piper Jaffray Healthcare Conference on
View HTML
Toggle Summary ArQule to Present Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium
Three poster presentations highlighting clinical data from ARQ 751-101 and preclinical data on ARQ 751 in combination with other agents BURLINGTON, Mass. --(BUSINESS WIRE)--Nov. 8, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting clinical and preclinical data on the
View HTML
Toggle Summary ArQule Reports Third Quarter 2018 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 31, 2018-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2018. For the quarter ended September 30, 2018 , the Company reported a net loss of $5,619,000 or $0.05
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.